Expanding Global Access Through Voluntary Licensing and Tech Transfer

Turning patented biomedical discoveries into affordable, widely available treatments requires aligned partnerships between innovator pharma and regional generic manufacturers. In this episode of Outsourcing Against the Outbreak, Charles Gore, Executive Director of the Medicines Patent Pool (MPP), breaks down how voluntary licensing models expand access across low- and middle-income markets. The conversation explores how MPP protects innovator commercial interests while managing quality compliance, the role of non-exclusive licensing in driving down therapy costs, and proactive pandemic preparedness agreements such as licensing baloxavir marboxil with Roche. Gore also details the operational realities of complex mRNA technology transfers across global networks, the business case for early access planning, and why building regional diagnostic capacity is essential to maximizing therapeutic impact.